The Impact Bridge

Translating China’s burgeoning healthcare sector into global opportunities.

[The Impact Bridge @theimpactbridge]

➡️

[The Impact Bridge @theimpactbridge]

Last week in #China #vaccine news (Dec.23-Dec.29) ➡️China’s CDE issued two new vaccine-related guidelines: “Guidelines for Statistical Principles in Vaccine Clinical Trials” and “Guidelines for Pharmaceutical Research and Evaluation of Conjugated Polysaccharide Vaccines”.

[The Impact Bridge @theimpactbridge]

- Newish Technology applied for clinical trials for NWRD09, a new #HPV therapeutic vaccine against HPV16-related tumors.
- @cansinobio_inc reported its recombinant shingles vaccine has completed all on-site work for Phase I trials conducted in Canada and now analysing data.

[The Impact Bridge @theimpactbridge]

➡️Rhegen Bio applied for clinical trials for its freeze-dried bivalent RSV mRNA vaccine.
➡️LVRNA101, an mRNA vaccine against HSV-2 jointly developed by LiveRNA Therapeutics Inc. and BCHTPharm, has been approved for clinical trials.

[The Impact Bridge @theimpactbridge]

Last week in #China #vaccine news (Dec.16-Dec.22)
➡️China’s State Council appointed Xia Gang as the new Vice Administrator of China's National Disease Control and Prevention Administration, replacing the retiring Chang Jile.

[The Impact Bridge @theimpactbridge]

➡️@cansinobio_inc announced acceptance of New Drug Application for its DTCP Infant.
➡️The company also announced the launch of Phase I/II clinical trials for its recombinant polio vaccine in Indonesia, with the first subject enrolled in the Phase I trial.
https://t.co/RjessveLyB

[The Impact Bridge @theimpactbridge]

➡️The Beijing Institute of Biological Products of @ChinaSinopharm received IND approval from China’s CDE for its #Mpox vaccine.
➡️@WantaiBio announced the successful completion of Phase I clinical trials for its hepatitis E vaccine in the US.

[The Impact Bridge @theimpactbridge]

Last week in #China #vaccine news (Dec.9-Dec.15)
Multiple updates on clinical trials:
➡️Suzhou Abogen Biosciences submitted application for clinical trials for its #RSV #mRNA vaccine, marking the third such candidate in China after submissions by NanoRibo and @sinovac.

[The Impact Bridge @theimpactbridge]

➡️Guangzhou Patronus Biotech has obtained approval to conduct clinical trials in China for its recombinant RSV vaccine, LYB005, which previously began Phase I trials in Australia in July.
➡️TheraVac launched Phase I trials of its recombinant #shingles vaccine (CHO cell).

[The Impact Bridge @theimpactbridge]

➡️@Sinovac has established a new subsidiary, Sinovac (Chengdu) Biotech, in Southwestern China. The subsidiary will focus on advancing its serum-free, Vero cell-based freeze-dried #rabies vaccine, which has completed Phase III trials.

[The Impact Bridge @theimpactbridge]

Last week in #China #vaccine news (Dec.2-Dec.8)
➡️Updates with mRNA vaccines
- @Sinovac applied for clinical trials for its freeze-dried #RSV mRNA vaccine.
- Youcare Pharmaceutical received approval from US FDA to conduct trials for its #shingles mRNA vaccine YKYY026.

[The Impact Bridge @theimpactbridge]

➡️1,000 doses of bivalent #HPV vaccine Cecolin were donated to Nepal as part of the “HPV Vaccine and Cervical Cancer Screening Technology Demonstration Project” funded by China’s Ministry of Science and Technology.